COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,544 Articles (22,881 medRxiv, 8,663 bioRxiv)

Most recent first Previous |  Page 1503: Articles 15021-15030  | Next

Effectiveness of mRNA COVID-19 Vaccines among Employees in an American Healthcare System
Shrestha, N. K., Nowacki, A. S., Burke, P. C., Terpeluk, P., Gordon, S. M.
10.1101/2021.06.02.21258231 — Posted: 2021-06-05 Discussion: Onsite
Health care use up to 6 months after COVID-19 in 700.000 children and adolescents: a pre-post study
Magnusson, K., Skyrud, K. D., Suren, P., Greve-Isdahl, M., Stordal, K., Kristoffersen, D. T., Telle, K. E.
10.1101/2021.06.02.21258211 — Posted: 2021-06-05
A Cluster-based Model of COVID-19 Transmission Dynamics
Shayak, B., Sharma, M. M.
10.1101/2021.06.02.21258243 — Posted: 2021-06-05
Efficacy of clarithromycin on COVID-19 pneumonia without oxygen administration; protocol for multicenter, open-label, randomized-controlled, 3-armed parallel group comparison, exploratory trial (CAME COVID study)
Yamamoto, K., Hosogaya, N., Sakamoto, N., Yoshida, H., Ishii, H., Yatera, K., Izumikawa, K., Yanagihara, K., Mukae, H.
10.1101/2021.06.02.21258257 — Posted: 2021-06-05
Classifying Texas counties using ARIMA Models on COVID-19 daily confirmed cases: the impact of political affiliation and face covering orders
Jiang, H., Pulins, B., Thiele, A.
10.1101/2021.06.02.21258221 — Posted: 2021-06-05
Tracking deaths can provide an indicator of latent COVID19 cases
Mandayam Rangayyan, Y., Kidambi, S., Raghavan, M.
10.1101/2021.06.02.21258217 — Posted: 2021-06-05
Human single-chain antibodies neutralize SARS-CoV-2 variants by engaging an essential epitope of the spike: a new weapon against COVID-19
Minenkova, O., Santapaola, D., Milazzo, F. M., Anastasi, A., Battistuzzi, G., Chiapparino, C., Rosi, A., Gritti, G., Borleri, G., Rambaldi, A., Dental, C., Viollet, C., Pagano, B., Salvini, L., Marra, E., Luberto, L., Rossi, A., Riccio, A., Merlo Pich, E., Santoro, M. G., De Santis, R.
10.1101/2021.06.04.447066 — Posted: 2021-06-04
A hybrid in silico approach reveals novel inhibitors of multiple SARS-CoV-2 variants
Jain, S., Talley, D. C., Baljinnyam, B., Choe, J., Hanson, Q., Zhu, W., Xu, M., Chen, C. Z., Zheng, W., Hu, X., Shen, M., Rai, G., Hall, M., Simeonov, A., Zakharov, A. V.
10.1101/2021.06.04.447130 — Posted: 2021-06-04
Screening of Botanical Drugs against SARS-CoV-2 Entry
Cao, J., Liu, Y., Zhou, M., Dong, S., Jia, X., Lan, X., Zhang, Y., Guo, J., Xiao, G., Wang, W.
10.1101/2021.06.03.447021 — Posted: 2021-06-04
Antibody Response after Second-dose of ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) among Health Care Workers in India: Final Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study
SINGH, A. K., Phatak, S. R., SINGH, R., Bhattacharjee, K., Singh, N. K., Gupta, A., Sharma, A.
10.1101/2021.06.02.21258242 — Posted: 2021-06-04 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).